| Domain | Curated finding | Suggested ontology/identifier | Evidence strength/notes |
|---|---|---|---|
| Disease identity | Classic Stüve-Wiedemann syndrome is a rare congenital bent-bone skeletal dysplasia with prominent dysautonomia; the literature also notes historical overlap with “Schwartz-Jampel syndrome type 2,” now considered the same LIFR-related condition. OMIM numbering is inconsistent across sources: some reviews cite **OMIM #601559**, while at least one review cites **OMIM #610559**; database validation is required before KB ingestion. | Disease label: **Stüve-Wiedemann syndrome**; legacy synonym: **Schwartz-Jampel syndrome type 2**; OMIM ID **requires database validation**; MONDO ID **requires database validation**; Orphanet ID **requires database validation** | Strong disease-definition evidence from landmark genetics and reviews; explicit OMIM ambiguity present in retrieved sources and should be reconciled against OMIM/Orphanet directly (pqac-00000000, pqac-00000005, pqac-00000001) |
| Data provenance | Current summary is derived from aggregated disease-level resources and literature synthesis, especially a 69-patient systematic review, plus primary molecular studies and case reports rather than EHR-scale datasets. | Evidence type labels: **systematic review**, **human clinical case series**, **primary human molecular study**, **model organism** | Useful for KB evidence grading; no large registry or EHR resource identified in retrieved evidence (pqac-00000000, pqac-00000016) |
| Etiology | Primary cause is **biallelic loss-of-function pathogenic variants in LIFR** causing defective cytokine receptor signaling. | **LIFR** gene; chromosome **5p13.1**; inheritance term: **autosomal recessive** | Landmark AJHG study mapped disease to 5p13.1 and identified null LIFR mutations in 19 families (pqac-00000010, pqac-00000012) |
| Genetic architecture | In 19 SWS/SJS2 families, **14 distinct LIFR mutations** were identified; **12/14** were predicted premature-termination variants, supporting a predominantly truncating/null allelic spectrum. | Variant classes: **frameshift**, **nonsense**, **splice-site**; germline origin: **germline** | Strong primary evidence for null-variant mechanism (pqac-00000013) |
| Founder effect / population genetics | An identical **653_654insT / c.653dup** frameshift was reported in families from the **United Arab Emirates**, suggesting a regional founder effect; disease burden is enriched in highly consanguineous populations. | Founder variant label: **LIFR c.653dup**; population note: **UAE founder effect** | Strong for founder effect in specific region; broader carrier frequency remains unavailable in retrieved evidence (pqac-00000013, pqac-00000002) |
| Inheritance | **Autosomal recessive** inheritance is consistently reported; consanguinity is common in affected families. | Inheritance: **autosomal recessive** | Strong and concordant across reviews and primary genetics papers (pqac-00000000, pqac-00000001, pqac-00000010) |
| Core prenatal phenotype | Prenatal ultrasound may show **mild-to-moderate micromelia**, **bowing of lower-limb bones** (tibia more than femur), **talipes**, and **camptodactyly**; later gestation may show **IUGR** and **oligohydramnios**. In one review, **8/10 (80%)** postnatally confirmed fetuses had prenatal skeletal abnormalities. | HPO labels: **Short long bones**, **Bowing of long bones**, **Talipes**, **Camptodactyly**, **Intrauterine growth restriction**, **Oligohydramnios**; IDs require validation | Moderate-strong; based on retrospective prenatal series summarized in review (pqac-00000019, pqac-00000020) |
| Core neonatal/infant phenotype | Typical early features include **short bowed limbs**, **camptodactyly**, **hypotonia/myotonia**, **feeding and swallowing difficulties**, **respiratory distress**, **hyperthermic episodes**, and **excessive/inappropriate sweating**. | HPO labels: **Bowing of long bones**, **Camptodactyly**, **Respiratory distress**, **Dysphagia**, **Hyperthermia**, **Hyperhidrosis**, **Hypotonia**; IDs require validation | Strong clinical consistency across reviews (pqac-00000001, pqac-00000004, pqac-00000016) |
| Dysautonomia / neuropathy | Dysautonomia includes temperature dysregulation, abnormal sweating, reduced pain sensation, and loss of reflexes such as **corneal** and **patellar** reflexes. | HPO labels: **Dysautonomia**, **Reduced pain sensation**, **Absent corneal reflex**, **Areflexia**; CL term suggestion: **sympathetic neuron** (ID requires validation) | Moderate-strong; emphasized in neuropathy-focused review (pqac-00000004, pqac-00000015) |
| Childhood survivor phenotype | Among survivors >2 years, orthopedic complications increase: **joint mobility restriction 81%**, **spinal deformations 77%**, **fractures 61%**. Dysautonomic symptoms tend to lessen with age, while skeletal morbidity accumulates. | HPO labels: **Joint contracture / restricted joint mobility**, **Scoliosis / spinal deformity**, **Fractures**, **Osteoporosis**; IDs require validation | Strong quantitative evidence from 69-patient systematic review (pqac-00000000, pqac-00000003) |
| Mechanism / molecular pathway | LIFR normally transduces signaling from IL-6 family cytokines and activates **JAK/STAT3**, with additional **MAPK** and **PI3K** pathway engagement. Most disease alleles destabilize LIFR mRNA or truncate the receptor, causing absent receptor protein and failure of downstream signaling. | GO/process labels: **JAK-STAT cascade**, **cytokine-mediated signaling pathway**, **regulation of bone development**, **autonomic nervous system development**; pathway labels only, IDs require validation | Strong primary/mechanistic evidence; classic causal chain is null LIFR → absent signaling → skeletal and autonomic defects (pqac-00000010, pqac-00000013) |
| Distinguishing related disorder | **IL6ST/GP130 deficiency** causes **extended Stüve-Wiedemann syndrome**, not classic SWS1. It shares skeletal/dysautonomic features but has broader GP130-dependent cytokine signaling failure and additional immune/renal/hematologic findings. | Related disease label: **extended Stüve-Wiedemann syndrome**; gene: **IL6ST** | Important curation distinction to avoid conflating classic LIFR disease with IL6ST-related phenotype expansion (pqac-00000008, pqac-00000011, pqac-00000014) |
| Anatomy affected | Primary systems: **skeletal system**, **peripheral/autonomic nervous system**, **respiratory system**, **feeding/swallowing apparatus**, and **eye/cornea** in some survivors. | UBERON labels: **long bone**, **spine**, **lung**, **esophagus/pharynx**, **cornea**; CL labels: **osteoblast**, **osteoclast**, **motor neuron**, **sympathetic neuron**; IDs require validation | Mechanistic-anatomic inference is supported by clinical phenotype and model data (pqac-00000003, pqac-00000010, pqac-00000012) |
| Diagnosis | Diagnosis is clinical-radiographic plus molecular confirmation. Key radiographic findings include **bowed femur/tibia**, **diaphyseal cortical thickening**, **wide metaphyses**, and **decreased bone density**. Genetic confirmation is by **LIFR sequencing**. | Diagnostic labels: **skeletal survey**, **molecular genetic testing**, **LIFR single-gene or panel testing**, **exome/genome sequencing** | Strong for radiographic phenotype and confirmatory genetic testing; no disease-specific biomarker identified (pqac-00000016, pqac-00000019) |
| Differential diagnosis | Main differentials among prenatal/neonatal bent-bone dysplasias include **campomelic dysplasia**, **kyphomelic dysplasia**, and **diastrophic dysplasia**. | Disease labels only; ontology IDs require validation | Moderate evidence from reviews; useful for prenatal and neonatal diagnostic workup (pqac-00000002, pqac-00000020) |
| Prognosis / mortality | Natural history is marked by high early mortality. In the 69-patient review, mortality was **42% before age 2** versus **10% after age 2**; **pulmonary arterial hypertension** was a poor prognostic factor with **63% mortality**. Respiratory failure is the leading cause of death. | Prognostic factor label: **pulmonary arterial hypertension**; HPO label: **Respiratory failure** | Strong quantitative prognosis evidence (pqac-00000000, pqac-00000016) |
| Development / cognition | Survivors often have delayed motor development, but **cognitive development is generally normal** in reported cases. | HPO labels: **Motor delay**, **Normal cognition/intellect**; IDs require validation | Moderate-strong consistency across reviews (pqac-00000001, pqac-00000003) |
| Current treatment | No curative or disease-modifying therapy is established; management is **supportive and multidisciplinary**. Core measures include **aspiration prevention**, **nasogastric tube or gastrostomy**, respiratory support/monitoring, and structured fever-management plans. | NCIT labels: **Gastrostomy**, **Nasogastric Intubation**, **Supportive Care**, **Multidisciplinary Care**; IDs require validation | Strong across reviews and 2024 case report (pqac-00000005, pqac-00000006, pqac-00000017) |
| Symptom-directed drugs | Recent case literature describes home protocols using **acetaminophen**, **ibuprofen**, and **bromocriptine** for hyperthermia escalation; these are supportive measures, not validated disease-specific therapies. | CHEBI/NCIT labels: **Acetaminophen**, **Ibuprofen**, **Bromocriptine**; IDs require validation | Limited evidence: case-report level only (2024), no controlled trials (pqac-00000006, pqac-00000017) |
| Orthopedic management | Supportive orthopedic care includes **physiotherapy**, **bracing**, **calcium/vitamin D**, **bisphosphonates** for bone fragility prevention, and corrective surgery; **telescopic intramedullary rodding** has been recommended to limit recurrence of deformity. | NCIT labels: **Physical Therapy**, **Orthotic Device**, **Bisphosphonate Therapy**, **Intramedullary Rod Placement**; IDs require validation | Moderate evidence from systematic review and survivor literature (pqac-00000003) |
| Ophthalmic / dental issues | Ocular surface problems and corneal reflex loss are reported; dental and ophthalmologic follow-up are part of multidisciplinary care, but evidence is sparse in retrieved sources. | HPO labels: **Corneal opacity**, **Neurotrophic keratopathy**; specialty care labels: **ophthalmology**, **dentistry**; IDs require validation | Low-moderate evidence in retrieved set; requires dedicated literature validation before structured frequency claims (pqac-00000003, pqac-00000018) |
| Anesthesia | Historically there were concerns about malignant hyperthermia risk, but recent case literature notes published SWS patients undergoing anesthesia without malignant hyperthermia episodes. | NCIT label: **General Anesthesia**; adverse-event label: **Malignant Hyperthermia** | Low-moderate evidence, mainly case-report/review level; should be interpreted cautiously (pqac-00000006, pqac-00000017) |
| Prevention / screening | Primary prevention is not applicable once genotype is inherited; practical prevention focuses on **genetic counseling**, **carrier screening in at-risk families/populations**, **prenatal diagnosis**, and potentially **preimplantation genetic testing** when familial variants are known. | Prevention labels: **Genetic Counseling**, **Carrier Screening**, **Prenatal Diagnosis**, **Preimplantation Genetic Testing**; IDs require validation | Strong rationale for recessive disease prevention, though disease-specific screening programs were not identified (pqac-00000020, pqac-00000016) |
| Clinical trials / advanced therapeutics | No disease-specific approved targeted therapy, gene therapy, RNA therapy, or interventional clinical trial was identified in the retrieved search. Gentamicin-mediated readthrough has been discussed experimentally for nonsense variants but remains nonstandard and toxicity-limited. | Intervention labels: **Gentamicin readthrough (experimental)**; trial status: **no disease-specific interventional trial identified** | Evidence for absence of standard targeted therapy is consistent; trial search returned no relevant active study in retrieved tooling (pqac-00000002, pqac-00000004) |
| Model organism | **Lifr-null mice** show severe developmental abnormalities with **perinatal lethality**, reduced fetal bone volume, increased osteoclasts, and neural defects, supporting causal roles in bone and nervous-system development. | Model label: **Lifr knockout mouse**; GO labels: **bone development**, **neuron development**; IDs require validation | Strong supportive model evidence, though not all human dysautonomic features are fully modeled (pqac-00000010, pqac-00000012) |
| Knowledge gaps | No robust prevalence/incidence estimate for general populations, no validated prognostic biomarker beyond clinical complications like PAH, no confirmed protective factors, no established modifier genes, and no omics-based diagnostic signature were identified in retrieved evidence. | KB flags: **data unavailable / not established** | Important negative curation points to avoid overstatement (pqac-00000000, pqac-00000003, pqac-00000004) |


*Table: This table condenses the main disease-knowledge-base fields for classic LIFR-related Stüve-Wiedemann syndrome, including identity, genetics, phenotype, mechanism, diagnosis, prognosis, treatment, prevention, and model evidence. It also flags key curation issues such as OMIM ambiguity and the need to distinguish classic SWS1 from IL6ST-related extended SWS.*